Search results for "Breakthrough"

showing 10 items of 55 documents

Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

2015

Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP).Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sle…

AdultMalemedicine.medical_specialtySettore MED/42 - Igiene Generale E ApplicataFentanylCohort StudiesPatient satisfactionNeoplasmsInternal medicineparasitic diseasesHumansPain ManagementMedicineProspective StudiesCancer painAdverse effectProspective cohort studyAdministration IntranasalAgedPain Measurementbusiness.industryBreakthrough PainMiddle AgedTolerabilityDiscontinuationAnalgesics OpioidFentanylBreakthrough pain; Cancer pain; Intranasal fentanyl; Tolerability; OncologyOncologyTolerabilityPatient SatisfactionAnesthesiaIntranasal fentanylFemaleSleepbusinessCancer painmedicine.drugCohort studySupportive Care in Cancer
researchProduct

Pharmacological management of cancer pain in children

2014

The aim of this review was to assess cancer pain management in children on the basis of research published in the last ten years. Nine were papers providing clinical data, with a minimum of ten patients. No controlled studies were found. Regardless of general principles and existing recommendations, clinical data should confirm the applicability of this concept. The trials published in the last years did not provide further information to improve cancer pain management in children, because of the experience and the low number of drugs used, reflecting only meaningful opinions of experts in the field. The amount and the quality of data still remain poor, as only 737 subjects (about 80 patien…

Analgesicsmedicine.medical_specialtybusiness.industryCancer pain Pediatric painBreakthrough PainPharmacological managementAlternative medicinePainSettore MED/41 - AnestesiologiaHematologyPharmacologyClinical trialOncologyOpioidNeoplasmsHumansMedicineChildbusinessAdverse effectOpioid analgesicsIntensive care medicineCancer painmedicine.drug
researchProduct

Strengths and Weaknesses of Cancer Pain Management in Italy: Findings from a Nationwide SIAARTI Survey

2022

Objectives: Despite guidelines, a large percentage of cancer patients continue to suffer from ineffectively treated pain. The authors undertook this survey to assess the strengths and weaknesses of cancer pain management in Italy. Design: This was a prospectively administered survey. Participants: The participants were anesthesiologists of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). Intervention: A 58-item questionnaire covered the demographics and features of cancer pain management in the Italian context. Results: The authors received responses from 611 pain therapists of 279 centers. Only 22% of physicians are exclusively pain therapists. Seve…

Breakthrough cancer pain; Cancer pain; Chronic pain; Neuropathic pain; Opioid; Pain management; SurveyLeadership and ManagementHealth PolicyBreakthrough cancer painChronic painHealth InformaticsOpioidNeuropathic painPain managementHealth Information ManagementSettore MED/41Cancer painSurveycancer pain; survey; breakthrough cancer pain; pain management; chronic pain; opioid; neuropathic painHealthcare; Volume 10; Issue 3; Pages: 441
researchProduct

Evaluating equilibrium and non-equilibrium transport of bromide and isoproturon in disturbed and undisturbed soil columns.

2007

19 pages; International audience; In this study, displacement experiments of isoproturon were conducted in disturbed and undisturbed columns of a silty clay loam soil under similar rainfall intensities. Solute transport occurred under saturated conditions in the undisturbed soil and under unsaturated conditions in the sieved soil because of a greater bulk density of the compacted undisturbed soil compared to the sieved soil. The objective of this work was to determine transport characteristics of isoproturon relative to bromide tracer. Triplicate column experiments were performed with sieved (structure partially destroyed to simulate conventional tillage) and undisturbed (structure preserve…

Bromides[SDE.MCG]Environmental Sciences/Global ChangesSoil science010501 environmental sciences01 natural sciences[ SDE.MCG.CPE ] Environmental Sciences/Global Changes/domain_sde.mcg.cpechemistry.chemical_compoundBromide[SDU.STU.GC]Sciences of the Universe [physics]/Earth Sciences/GeochemistryTRACER[ SDE.MCG.SIC ] Environmental Sciences/Global Changes/domain_sde.mcg.sic[ SDU.ENVI ] Sciences of the Universe [physics]/Continental interfaces environmentWater MovementsSoil PollutantsEnvironmental Chemistry[SDU.ENVI]Sciences of the Universe [physics]/Continental interfaces environment0105 earth and related environmental sciencesWater Science and Technology[SDE.MCG.SIC]Environmental Sciences/Global Changes/domain_sde.mcg.sicHerbicidesPhenylurea CompoundsBreakthrough curvesModelingSorption04 agricultural and veterinary sciences[ SDU.STU.GC ] Sciences of the Universe [physics]/Earth Sciences/Geochemistry[SDE.MCG.CPE]Environmental Sciences/Global Changes/domain_sde.mcg.cpeBulk density6. Clean waterTillage[ SDE.MCG ] Environmental Sciences/Global ChangesPermeability (earth sciences)Models ChemicalchemistryLoamSoil waterBromide040103 agronomy & agriculture0401 agriculture forestry and fisheriesAdsorptionIsoproturonGeologyHYDRUS-1D
researchProduct

The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain

2021

Simple Summary The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain. This prospective study showed that in this population, BTcP prevalence was 69.8%. Many patients did not achieve a sufficient level of satisfaction with BTcP medications, particularly with oral morphine. Data also suggest that better optimization of background analgesia, though apparently acceptable, may limit the number of BTcP episodes. Abstract The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background p…

Cancer Researchmedicine.medical_specialtyPain relieflcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAnalgesic therapyInternal medicineEpidemiologymedicineIn patientOral morphinebreakthrough cancer pain; opioids; dosesbusiness.industryLow doseBreakthrough cancer painlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdosesOpioidsOncologyDose030220 oncology & carcinogenesisCancer painbusiness030217 neurology & neurosurgery
researchProduct

Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment

2019

e23135 Background: Breakthrough cancer pain (BTcP) is one of the most common symptoms related with the disease and its treatment. Its management differs from that of chronic pain but there is not a wide consensus about fundamental aspects of BTcP definition, diagnosis, follow-up, and management. The objective of this study promoted by ECO Foundation, is to reach a consensus on the follow-up of patients with BTcP under opioid treatment. Methods: This work was conducted using a modified Delphi method organized in two rounds and involving a panel of 84 medical oncologists. A questionnaire of 66 items was developed. The items proposed to reach a consensus included the following topics: 1) When…

Cancer Researchmedicine.medical_specialtybusiness.industryBreakthrough PainChronic painCancerDiseasemedicine.diseaseOncologyOpioidPain controlInternal medicineMedicinebusinessIntensive care medicineCancer paincomputerDelphimedicine.drugcomputer.programming_languageSN Comprehensive Clinical Medicine
researchProduct

Treating breakthrough pain in oncology

2018

Breakthrough cancer pain (BTcP) is an episode of severe intensity in patients receiving an adequate treatment with opioids able to provide at least mild analgesia. BTcP is a heterogeneous condition as episodes vary between individuals. The aim of this article is to review the pharmacologic options for the management of BTcP. Areas covered: Recent reviews revealed that transmucosal preparations of fentanyl provided superior and more rapid pain relief as compared to placebo and oral morphine within the first 30 min after dosing. Few comparison studies among fentanyl products have been performed. Although dose titration has been recommended for years, a meaningful dosing, according to the leve…

Dose-Response Relationship DrugMorphinebusiness.industryBreakthrough PainBreakthrough PainAdministration BuccalAdministration OralCancer PainAnalgesics OpioidFentanyl03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisAnesthesiaHumansMedicinePharmacology (medical)In patientbusinessCancer pain030217 neurology & neurosurgeryExpert Review of Anticancer Therapy
researchProduct

Breakthrough pain: On the road again

2009

DrugAnesthesiology and Pain MedicineText miningbusiness.industryBreakthrough Painmedia_common.quotation_subjectMEDLINEMedicineOpioid analgesicsbusinessBioinformaticsmedia_commonEuropean Journal of Pain
researchProduct

New drugs for pain management in advanced cancer patients.

2017

Advanced cancer patients represent a frail population, often requiring aggressive pain management, particularly in the late stage of disease, when untreated pain is one the most important causes of suffering. Areas covered: In the last decade, a series of new analgesics have been introduced in the market to offer additional options amongst existent drugs. The characteristics of these drugs, their efficacy and tolerability are examined on the basis of existent studies. Expert opinion: Although new analgesic preparations have been developed in recent years, no specific drug has provided a better analgesic performance in comparison with others. Some technologies have been developed to increase…

Drugmedicine.medical_specialtymedia_common.quotation_subjectAnalgesicPopulationPainDiseasePain ladder03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Adverse effectIntensive care medicineeducationmedia_commonPain MeasurementPharmacologyeducation.field_of_studyAnalgesicsbusiness.industryBreakthrough PainGeneral MedicineAnalgesics OpioidTolerability030220 oncology & carcinogenesisAnesthesiaCancer painbusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Breakthrough Pain (BTP) in Opioid-Tolerant Cancer Patients: A Pan-European Open-Label Multicentre Study with Fentanyl Buccal Tablet (FBT)

2012

ABSTRACT BTP, a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain, is a common problem in cancer patients. FBT is indicated for the treatment of BTP in adults with cancer already receiving maintenance opioid therapy for chronic cancer pain and should be titrated to an effective dose that provides adequate analgesia and minimises undesirable events. In this study, patients entered a screening period and were randomized during an open-label titration period to a starting FBT dose of 100 µg (group A) or 200 µg (group B) to identify the FBT effective dose and then treated in an open-label period (for 8 BTP episodes). Patients' inclusion followed…

Exacerbationbusiness.industryBreakthrough PainRectumBone metastasisHematologymedicine.diseaseEffective dose (pharmacology)Group Bmedicine.anatomical_structureOncologyOpioidAnesthesiaFentanyl Buccal Tabletmedicinebusinessmedicine.drugAnnals of Oncology
researchProduct